Science Explorer Interactive view Map
Company · Vienna · Austria

AFFiRiS (Austria)

Research works
29
▼ 79% vs 2013–17
Citations
1.1k
39.2 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
48%
world 28%

Not ranked overall: AFFiRiS (Austria) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which keywords describe research at AFFiRiS (Austria)?

By fractional works in all years, weighted toward what it does more of than the world: Neurodegeneration, Neuroinflammation, Oxidative Stress, Amyloid Hypothesis, Tau Pathology, Cytokines, Inflammation and Microglia.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Neurodegeneration9▲ 104×7 topics
  2. Neuroinflammation8▲ 98×3 topics
  3. Oxidative Stress8▲ 14×8 topics
  4. Amyloid Hypothesis5▲ 298×1 topic
  5. Tau Pathology5▲ 298×1 topic
  6. Inflammation4▲ 6.7×12 topics
  7. Cytokines4▲ 55×4 topics
  8. Microglia3▲ 127×2 topics
  9. Innate Immunity3▲ 30×4 topics
  10. Mitochondrial Dysfunction3▲ 26×6 topics
  11. C-Reactive Protein2▲ 100×2 topics
  12. Ischemic Stroke2▲ 63×2 topics
  13. Astrocytes2▲ 175×1 topic
  14. Synaptic Pruning2▲ 175×1 topic
  15. Parkinson's Disease2▲ 31×3 topics
  16. Alzheimer's Disease2▲ 24×5 topics
  17. Cholesterol-lowering2▲ 124×1 topic
  18. Dopaminergic Neurons2▲ 96×2 topics
  19. Statins2▲ 77×1 topic
  20. Diagnostic Criteria2▲ 28×3 topics
  21. Schizophrenia2▲ 43×3 topics
  22. Molecular Docking2▲ 37×1 topic
  23. Virtual Screening2▲ 75×1 topic
  24. Cardiovascular Disease1▲ 4.5×4 topics
  25. Atherosclerosis1▲ 12×3 topics
  26. Epidemiology1◆ 1.15×4 topics
  27. Genetic Risk Factors1▲ 93×1 topic
  28. Obesity1▲ 6.0×4 topics
  29. a-Synuclein1▲ 93×1 topic
  30. Cancer1▲ 3.0×9 topics
  31. Depression1▲ 5.4×2 topics
  32. Antigen Presentation1▲ 38×2 topics
  33. Insulin Resistance1▲ 7.9×3 topics
  34. T Cell Activation1▲ 77×2 topics
  35. Toxicology1▲ 19×2 topics
  36. Cancer Progression1▲ 16×2 topics
  37. Cell Signaling1▲ 11×2 topics
  38. Epitope Prediction1▲ 185×1 topic
  39. Neurodegenerative Diseases1▲ 16×3 topics
  40. Peptide-MHC Binding1▲ 185×1 topic

Which research topics does AFFiRiS (Austria) publish most on?

By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune Cell Function and Interaction and Muscle Physiology and Disorders.

  1. 1 Cancer Immunotherapy and Biomarkers Oncology 0 works
  2. 2 CAR-T cell therapy research Oncology 0 works
  3. 3 Immune Cell Function and Interaction Immunology 0 works
  4. 4 Muscle Physiology and Disorders Molecular Biology 0 works
  5. 5 Genetic Neurodegenerative Diseases Cellular and Molecular Neuroscience 0 works
  6. 6 Neurological disorders and treatments Neurology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available48.3%not open51.7%

World: 28% of research is openly available.

with international co-authors29.8%domestic only70.2%

World: 19% is written across borders.

How has AFFiRiS (Austria)'s research output changed?

Output in 2018–2022 was 79% lower than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Vienna

All research institutions in Vienna

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.